Dupilumab-Associated Sweet Syndrome

Cutis. 2023 Jun;111(6):E7-E9. doi: 10.12788/cutis.0798.

Abstract

Sweet syndrome (SS), also known as acute febrile neutrophilic dermatosis, is characterized by the abrupt appearance of edematous and erythematous papules, plaques, or nodules on the skin that have a distinct histopathologic appearance. Several subtypes of SS exist, including classic (also referred to as idiopathic) and drug induced. Although multiple medications have been implicated as causative agents, we present a rare case of SS caused by dupilumab, a monoclonal antibody therapy, used in the treatment of severe eosinophilic asthma and other conditions. Clinicians should be aware of this potential adverse reaction, as prompt recognition and treatment are essential.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Asthma* / drug therapy
  • Female
  • Humans
  • Immunotherapy
  • Middle Aged
  • Skin
  • Sweet Syndrome* / chemically induced

Substances

  • Antibodies, Monoclonal, Humanized
  • dupilumab